Regulatory Disclosure Context

This press release is submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing a significant regulatory certification achievement.

Certification Details

CORONA Remedies Limited has received Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (ANVISA) for its manufacturing facility located at Bhayla, Ahmedabad. The certification covers both:

  • Oral Solid Dosage (OSD) manufacturing facility
  • Women's Hormone manufacturing facility

Strategic Significance and Quality Philosophy

The certification reinforces the company's commitment to its "One World, One Quality" philosophy, emphasizing consistent and uncompromised quality standards across global operations. This represents the company's third major GMP accreditation, building on:

  • EU-GMP approvals for Women's Hormone and OSD facilities
  • EAEU-GMP certification for the OSD facility

Market Context and Opportunity

Brazil represents one of the largest pharmaceutical markets in Latin America with an estimated market size of USD 44 billion. This certification positions CORONA Remedies to potentially access this significant market opportunity, particularly for pharmaceutical manufacturers with strong quality systems and regulatory capabilities.

Management Commentary

Mr. Viral Sitwala, Executive Director of CORONA Remedies Limited, commented: "Quality has always been central to the way we work at CORONA Remedies. Our philosophy of 'One World, One Quality' reflects our belief that the standards we must remain consistent and uncompromised. The ANVISA GMP certification for our Bhayla manufacturing facility is an important recognition of the systems, discipline, and collective efforts that go into maintaining these standards."

Business Focus Clarification

While achieving international certifications, the company emphasized that India remains its primary market, contributing over 96% of its revenue. The certifications primarily serve to strengthen manufacturing credentials rather than signal an immediate shift in market focus.

Company Background

CORONA Remedies Limited (CIN: L24231GJ2004PLC044656) is an India-focused pharmaceutical company founded in 2004, engaged in development, manufacturing, and marketing across key therapeutic areas including:

  • Women's Healthcare
  • Cardio-Diabetes
  • Pain Management
  • Urology

The company has established its presence through scientific expertise, brand building, manufacturing excellence, and quality-driven operations.

Disclaimer Note

The document contains standard forward-looking statements disclaimer noting that expectations are based on management's current views and assumptions, subject to known and unknown risks and uncertainties that could cause actual results to differ materially.